Trials / Completed
CompletedNCT05201937
A Study of JNJ-64281802 in Healthy Adult Participants
A Phase 1, Open-Label Study in Healthy Adult Participants to Assess the Pharmacokinetics of JNJ-64281802 Administered as Different Multiple Dose Regimens
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 33 (actual)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the pharmacokinetics (PK) of JNJ-64281802 in healthy participants when administered in different multiple dose regimens and as different dose strengths.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JNJ-64281802 | JNJ-64281802 tablets will be administered orally as per the defined regimens. |
Timeline
- Start date
- 2022-02-23
- Primary completion
- 2022-12-11
- Completion
- 2022-12-11
- First posted
- 2022-01-21
- Last updated
- 2025-03-30
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT05201937. Inclusion in this directory is not an endorsement.